Daniel P Bradley
Overview
Explore the profile of Daniel P Bradley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
291
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bradley D, Valkner C, Li Q, Gasonoo M, Meyers M, Prifti G, et al.
PLoS Pathog
. 2025 Feb;
21(2):e1012920.
PMID: 39928681
Hepatitis B virus (HBV) ribonuclease H (RNaseH) inhibitors are a potent class of antivirals that prevent degradation of the viral pregenomic RNA during reverse transcription and block formation of mature...
2.
Aktas O, Ziemssen F, Ziemssen T, Klistorner A, Butzkueven H, Izquierdo G, et al.
Mult Scler Relat Disord
. 2024 Dec;
93:106185.
PMID: 39662163
Background: The randomized, phase 2 RENEW trial (NCT01721161) evaluated efficacy/safety of opicinumab (anti-LINGO-1) versus placebo in patients with first-episode unilateral acute optic neuritis (AON). Although no significant differences in the...
3.
Jones T, Tavis J, Li Q, Riabova O, Monakhova N, Bradley D, et al.
J Med Chem
. 2023 Aug;
66(17):12459-12467.
PMID: 37611244
Hepatitis B virus (HBV) is a hepatotropic DNA virus that replicates by reverse transcription. It chronically infects >296 million people worldwide, including ∼850,000 in the USA, and kills 820,000 annually...
4.
Elliott C, Rudko D, Arnold D, Fetco D, Elkady A, Araujo D, et al.
Mult Scler
. 2023 Apr;
29(6):680-690.
PMID: 37036134
Background: Paramagnetic rim lesions (PRLs) and slowly expanding lesions (SELs) have been posited as markers of chronic active lesions (CALs). Objective: To assess the lesion-level concordance of PRLs and SELs...
5.
Wang S, Ren Y, Li Q, Wang Y, Jiang X, Xu S, et al.
Bioorg Chem
. 2022 Oct;
129:106192.
PMID: 36265355
Capsid assembly modulators (CAMs) represent a novel class of antiviral agents targeting hepatitis B virus (HBV) capsid to disrupt the assembly process. NVR 3-778 is the first CAM to demonstrate...
6.
Tajwar R, Bradley D, Ponzar N, Tavis J
Protein Sci
. 2022 Sep;
31(10):e4421.
PMID: 36173165
Hepatitis B virus (HBV) chronically infects >250 million people. It replicates by a unique protein-primed reverse transcription mechanism, and the primary anti-HBV drugs are nucleos(t)ide analogs targeting the viral polymerase...
7.
Beynon V, George I, Elliott C, Arnold D, Ke J, Chen H, et al.
BMJ Neurol Open
. 2022 Jun;
4(1):e000240.
PMID: 35720980
Objective: Slowly expanding lesions (SELs), a subgroup of chronic white matter lesions that gradually expand over time, have been shown to predict disability accumulation in primary progressive multiple sclerosis (MS)...
8.
Bradley D, ODea A, Woodson M, Li Q, Ponzar N, Knier A, et al.
Antimicrob Agents Chemother
. 2021 Oct;
66(1):e0161721.
PMID: 34694883
The α-hydroxytropolones (αHTs) are troponoid inhibitors of hepatitis B virus (HBV) replication that can target HBV RNase H with submicromolar efficacies. αHTs and related troponoids (tropones and tropolones) can be...
9.
Elliott C, Momayyezsiahkal P, Arnold D, Liu D, Ke J, Zhu L, et al.
Brain Commun
. 2021 Sep;
3(3):fcab176.
PMID: 34557664
Normal-appearing white matter is far from normal in multiple sclerosis; little is known about the precise pathology or spatial pattern of this alteration and its relation to subsequent lesion formation....
10.
Ma Y, Zhao S, Ren Y, Cherukupalli S, Li Q, Woodson M, et al.
Eur J Med Chem
. 2021 Aug;
225:113780.
PMID: 34438123
GLS4, a potent antiviral drug candidate, has been widely studied and entered into phase II clinical trials. Nevertheless, the therapeutic application of GLS4 is limited due to poor water solubility,...